Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.32 USD
+0.37 (3.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.33 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Inovio Pharmaceuticals (INO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.92 | $40.00 | $9.50 | 63.65% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Inovio Pharmaceuticals comes to $17.92. The forecasts range from a low of $9.50 to a high of $40.00. The average price target represents an increase of 63.65% from the last closing price of $10.95.
Analyst Price Targets (6 )
Broker Rating
Inovio Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/INO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Hold | Hold |
5/14/2024 | Stephens | Sudan Loganathan | Not Available | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Hold | Hold |
1/4/2024 | JMP Securities | Roy Buchanan | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 6 |
Average Target Price | $17.92 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -1.15 |